PDC*line Pharma

PDC*line Pharma, founded in 2014 and headquartered in Belgium, is pioneering a novel class of off-the-shelf cancer immunotherapies based on its proprietary Plasmacytoid Dendritic Cell line (PDC*line). As a clinical-stage biotechnology company, it focuses on developing cutting-edge cancer vaccines. The company's flagship product, PDC*lung, has shown promising Phase I/II results for lung cancer in 2024 following a successful first-in-human Phase Ib study in melanoma.

Following these advances, PDC*line Pharma is preparing a randomized Phase II trial for lung cancer and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). With a successful track record, the company has raised €61M in equity and non-dilutive funding and sealed a strategic €108M licensing agreement with LG Chem Life Science in Asia. Investors include Korea Investment Partners, Belgian Federal Investment, and others, reflecting strong confidence in the company's potential.